Myxovirus resistance protein A (MxA) polymorphism is associated with IFNβ response in Iranian multiple sclerosis patients
- 217 Downloads
Multiple sclerosis (MS) is a heterogeneous immune-related demyelinating disorder of central nervous system with several genetic and environmental factors contributing in its pathogenesis or patients’ response to therapies. Myxovirus resistance protein A (MxA) is among the genes which are induced by IFNβ and are involved in the MS pathogenesis and/or response to IFNβ. In the present case-control study, we evaluated the association between three SNPs at nt −123 (A or C, rs17000900), nt −88 (G or T, rs2071430), and nt +20 (A or C, rs464138) and MS risk as well as treatment response in a population of Iranian MS patients including 146 IFNβ responders and 85 non-responders as well as 180 healthy controls. The AGA (−123, −88, +20) haplotype was more frequent in controls compared with MS cases (P = 0.038, OR (95% CI) = 1.77 (1.03–3.02)). Of particular note, the frequency of rs464138 AA genotype was significantly higher in responders compared with non-responders. However, the allele and genotype frequencies of other SNPs were not significantly different among patient subtypes or between patients and controls. Besides, we have demonstrated that CGC, ATA, and AGA (−123, −88, +20) haplotypes were significantly associated with IFNβ response in MS patients. As SNPs on MxA promoter region might participate in MS patients’ response to IFNβ, prior patients genotyping may increase the rate of responsiveness and help in individualized selection of treatment options.
KeywordsMultiple sclerosis MxA Polymorphism
This research was supported by department of medical genetics of Shahid Beheshti University of medical science of Iran. Grant number: 11186.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Hamedani SY, Taheri M, Omrani MD, Sajjadi E, Mazdeh M, Panah AST, Sayad A (2016) Up regulation of MMP9 gene expression in female patients with multiple sclerosis. Hum Antibodies (Preprint):1–6Google Scholar
- 2.Etemadifar M, Nourian SM, Akbari M, Abtahi SH, Nasri P, Fereidan-Esfahani M (2015) The distinctive contrast of multiple sclerosis epidemiology between Persians and Armenian minority community of Isfahan city, Iran. Neurol Sci 36(4):657–658. doi: 10.1007/s10072-014-2013-0 CrossRefPubMedGoogle Scholar
- 4.Bertolotto A, Capobianco M, Amato MP, Capello E, Capra R, Centonze D, Di Ioia M, Gallo A, Grimaldi L, Imberti L, Lugaresi A, Mancinelli C, Marrosu MG, Moiola L, Montanari E, Romano S, Musu L, Paolicelli D, Patti F, Pozzilli C, Rossi S, Salvetti M, Tedeschi G, Tola MR, Trojano M, Zaffaroni M, Malucchi S (2014) Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian multiple sclerosis study group (vol 35, pg 307, 2014). Neurol Sci 35(10):1645–1646. doi: 10.1007/s10072-014-1649-0 CrossRefGoogle Scholar
- 5.Esposti LD, Piccinni C, Sangiorgi D, Perrone V, Aledda L, Marrosu MG, Lombardo F (2017) Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs. Neurol Sci. doi: 10.1007/s10072-016-2806-4 PubMedGoogle Scholar
- 9.Bertolotto A, Gilli F, Sala A, Audano L, Castello A, Magliola U, Melis F, Giordana MT (2001) Evaluation of bioavailability of three types of IFNβ in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 256(1):141–152CrossRefPubMedGoogle Scholar
- 13.Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. doi: 10.1002/ana.22366 CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Cunningham S, Graham C, Hutchinson M, Droogan A, O’Rourke K, Patterson C, McDonnell G, Hawkins S, Vandenbroeck K (2005) Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes. Clin Pharmacol Ther 78(6):635–646. doi: 10.1016/j.clpt.2005.08.018 CrossRefPubMedGoogle Scholar
- 15.Suzuki F, Arase Y, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Takagi K, Satoh J, Kumada H (2004) Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat 11(3):271–276. doi: 10.1111/j.1365-2893.2004.00509.x CrossRefPubMedGoogle Scholar
- 16.Noguchi S, Hijikata M, Hamano E, Matsushita I, Ito H, Ohashi J, Nagase T, Keicho N (2013) MxA transcripts with distinct first exons and modulation of gene expression levels by single-nucleotide polymorphisms in human bronchial epithelial cells. Immunogenetics 65(2):107–114. doi: 10.1007/s00251-012-0663-8 CrossRefPubMedGoogle Scholar
- 19.Hijikata M, Mishiro S, Miyamoto C, Furuichi Y, Hashimoto M, Ohta Y (2001) Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (−123 and -88) in vivo and in vitro. Intervirology 44(6):379–382. doi: 10.1159/000050075 CrossRefPubMedGoogle Scholar
- 23.Liggett T, Melnikov A, Tilwalli S, Yi QL, Chen HY, Replogle C, Feng X, Reder A, Stefoski D, Balabanov R, Levenson V (2010) Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci 290(1–2):16–21. doi: 10.1016/j.jns.2009.12.018 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Ghosh AK, Bhattacharyya S, Lafyatis R, Farina G, Yu J, Thimmapaya B, Wei J, Varga J (2013) p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-β: epigenetic feed-forward amplification of fibrosis. J Investig Dermatol 133(5):1302–1310CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Rahmani Z, Blouin JL, Creaugoldberg N, Watkins PC, Mattei JF, Poissonnier M, Prieur M, Chettouh Z, Nicole A, Aurias A, Sinet PM, Delabar JM (1989) Critical role of the D21s55 region on chromosome-21 in the pathogenesis of down syndrome. Proc Natl Acad Sci USA 86(15):5958–5962. doi: 10.1073/pnas.86.15.5958 CrossRefPubMedPubMedCentralGoogle Scholar